Novartis Gleevec Label Updated With Cardiovascular Risk Language
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Revised labeling for Novartis'Gleevec (imatinib) advises that patients taking the medication who have cardiac disease or are at risk for cardiac failure should be closely monitored
You may also be interested in...
Novartis/Idenix HCV Studies Altered For GI Safety; Five Gleevec sNDAs Pending
Idenix’ revision to the dosing scheme across its Phase IIb clinical program for valopicitabine reflects the firm’s and FDA’s concern that serious gastrointestinal side effects could represent key dose-limiting adverse events for the hepatitis C agent.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product